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New emerging influenza viruses with pandemic potentials were occurred in recent years, e.g. H5N1 in 1997, 
H1N1 in 2009, and H7N9 in 2013. The demand of producing pandemic influenza vaccines for human use with 
quick supply is high. For the cell-based pandemic influenza vaccines, we proposed a flow-through 
chromatography purification process. This process has only involved few purification steps and is easy to 
operate. Vero- and MDCK- cell derived avian influenza viruses including H5N1 and H7N9 were purified 
efficiently by the process proposed. 
  
The presented purification process consisted of clarification, inactivation, concentration, anion exchange 
chromatography (Capto Q), size exclusion and adsorption chromatography (Capto Core 700), diafiltration and 
sterile filtration. In the chromatography steps, cell DNA and protein were removed remarkably, and the virus 
were flowed through these columns. The flow rate was set as fast as 250 cm/min. The loading volume of virus 
solution was up to 50 times of column volume (CV).The DNA was removed over 90% after using Capto Q 
column, and was further removed by Capto Core 700 column. The overall removal rate of cellular DNA was 
more than 99%. The HA recovery rates of H5N1 and H7N9 influenza virus from Vero and MDCK cells were 20 
to 40%. The DNA concentration of all purified bulks met the regulatory requirement of 10ng per dose. The 
developed purification process is simple and efficient, and it is suitable for purification of various influenza virus 
strains and can be used for the pandemic influenza vaccine production. 
 
 
 
